Lipofene

Fenofibrate, the active ingredient in Lipofene, is a fibrate presented as an oral tablet for oral use. It is classified as a lipid‑lowering agent and works by activating peroxisome proliferator‑activated receptor alpha (PPARα), which increases the breakdown of triglyceride‑rich lipoproteins and raises high‑density cholesterol. The medication is indicated for adults with primary hypercholesterolemia, hypertriglyceridemia, or mixed dyslipidemia to help achieve target lipid levels.

GNH USA supplies Lipofene as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, transplant centres and oncology centres worldwide, providing reliable sourcing and regulatory support for bulk and retail needs.

Fenofibrate is used to manage disorders of lipid metabolism that increase cardiovascular risk.

Hypercholesterolemia: reduces LDL‑cholesterol and total cholesterol levels. Hypertriglyceridemia: lowers elevated triglyceride concentrations. Mixed dyslipidemia: improves the overall lipid profile by decreasing triglycerides and LDL while increasing HDL.

Fenofibrate may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Gastrointestinal discomfort such as nausea, abdominal pain or dyspepsia. - Headache or dizziness. - Elevated liver enzymes detected on routine testing. - Muscle pain or weakness without severe injury. - Skin rash or pruritus.

Serious or Rare Side Effects: - Rhabdomyolysis, especially when combined with statins. - Severe hepatic injury or cholestatic jaundice. - Acute pancreatitis. - Gallstone formation. - Anaphylactic or severe allergic reactions.

Before initiating therapy, clinicians should evaluate patient-specific risk factors and monitor laboratory parameters.

Monitor liver function: obtain baseline transaminases and repeat periodically. Assess renal function: adjust use in patients with significant renal impairment. Avoid in active gallbladder disease: fenofibrate can promote gallstone formation. Caution with concomitant statins: increased risk of myopathy and rhabdomyolysis. Pregnancy and lactation: use only if potential benefit justifies potential risk. Store at ambient temperature: keep in the original container, protect from moisture and light.

Fenofibrate can interact with several drug classes, altering efficacy or safety.

Major Interactions (Avoid): - Gemfibrozil: markedly increases risk of myopathy and rhabdomyolysis. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): raise fenofibrate plasma concentrations. - High‑dose statins (e.g., rosuvastatin): elevate risk of severe muscle toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: fenofibrate may potentiate anticoagulant effect, requiring INR monitoring. - Oral contraceptives: may attenuate lipid‑lowering response. - Thyroid hormone replacement: can modify lipid parameters, necessitating periodic lipid assessment.